Core Insights - Bio-Techne Corporation reported strong financial results for the third quarter ending March 31, 2025, with a net sales increase of 4% to $316.2 million and organic revenue growth of 6% compared to the prior year [6][8][23] - The company achieved an adjusted operating margin of 34.9%, up 190 basis points from the previous year, driven by profitability initiatives and volume leverage [4][9][30] - GAAP earnings per share (EPS) decreased to $0.14 from $0.31 in the same quarter last year, while adjusted EPS increased to $0.56 from $0.48 [7][9][28] Financial Performance - Net sales for the third quarter were $316.2 million, a 4% increase year-over-year, with organic revenue growth of 6% [6][8] - GAAP operating income decreased by 42% to $38.7 million, resulting in a GAAP operating margin of 12.2%, down from 22.1% in the prior year [7][30] - Adjusted operating income rose 11% to $110.3 million, with an adjusted operating margin of 34.9% compared to 33.0% in the prior year [9][30] Segment Performance - The Protein Sciences segment reported net sales of $227.7 million, a 6% increase from $214.6 million in the same quarter last year, with an organic revenue growth of 7% [11][30] - The Diagnostics and Spatial Biology segment achieved net sales of $89.2 million, a 2% increase from $87.5 million, with organic revenue growth of 2% [12][30] Non-GAAP Financial Measures - Adjusted EPS for the third quarter was $0.56, an increase from $0.48 in the same quarter last year [9][28] - Adjusted EBITDA for the quarter was $122.2 million, compared to $109.3 million in the prior year [31] - The non-GAAP adjusted tax rate was reported at 21.5%, consistent with the previous year [28][29]

Core Points - Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for the quarter ended March 31, 2025, payable on May 30, 2025, to shareholders of record on May 19, 2025 [1] - The company has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock, starting May 8, 2025, replacing the previous program [2] - Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people globally [3] Dividend Information - The quarterly dividend is set at $0.08 per share for the quarter ended March 31, 2025 [1] - The dividend payment date is May 30, 2025, with a record date of May 19, 2025 [1] Share Repurchase Program - The new share repurchase program allows for the repurchase of up to $500 million of common stock [2] - The program's execution will depend on share price, economic conditions, and regulatory requirements [2] - The company retains the right to suspend, amend, or discontinue the program at any time [2] Company Overview - Bio-Techne is a global life sciences company providing tools and bioactive reagents for research and clinical diagnostics [3] - The company's products support scientific investigations into biological processes and disease progression, aiding drug discovery and clinical testing [3] - Bio-Techne has a diverse portfolio with thousands of products [3]

Summary⚈ Congresswoman April McClain Delaney bought Bio-Techne stock twice in April 2025.⚈ The stock has dropped nearly 30% year-to-date and remains unprofitable post-purchase.⚈ Delaney’s committee roles suggest potential informational advantages in biotech-related decisions.Finbold’s congressional trading radar has recently picked up a suspicious stock bet made by Maryland congresswoman April McClain Delaney involving a low-profile biotech stock. The representative purchased Bio-Techne Corp stock (NASDAQ: ...

Core Viewpoint - Cyber Enviro-Tech, Inc. is conducting critical testing of its advanced water purification technology for the oil and gas industry, which could lead to contracts valued at over $100 million annually if successful [1][4]. Group 1: Technology and Testing - The testing aims to purify produced water, a byproduct of oil and gas extraction, which typically contains high concentrations of salts, hydrocarbons, heavy metals, and other contaminants [2]. - The goal is to reduce Total Dissolved Solids levels from 300,000 parts per million to the EPA standard of 500 ppm [2]. - Successful verification by independent laboratory results would enable the recycling of produced water for reuse in the oil industry, providing a more environmentally responsible and cost-effective alternative to deep underground injection [3]. Group 2: Environmental Impact - The ability to purify produced water to EPA standards has significant implications for water conservation and environmental sustainability [4]. - In Texas alone, over 10 billion barrels of produced water are injected underground each year, which removes vast quantities from the usable water supply [3]. Group 3: Company Overview - Cyber Enviro-Tech, Inc. operates internationally in eco-conscious oil sludge, water, and soil remediation projects, utilizing proprietary bioremedial materials and technologies [5]. - The company integrates Fourth Industrial Revolution technologies, including machine learning, artificial intelligence, cloud computing, and SCADA systems, alongside non-chemical bioremediation techniques [5].

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to report its third-quarter fiscal 2025 results on May 7, with positive earnings and revenue growth anticipated based on recent performance and market trends [1][2]. Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Bio-Techne's revenues is $315.2 million, reflecting a 3.9% increase from the previous year [2]. - The consensus estimate for EPS is projected at 51 cents, indicating a 6.3% year-over-year improvement [2]. - Recent estimates for EPS have decreased by 1.9% over the past 30 days [2]. Group 2: Segment Performance Insights - The Protein Sciences segment is expected to benefit from its protein analysis portfolio and GMP protein business, with revenues estimated at $224.7 million, up 4.7% from the prior year [3][5]. - The Diagnostics and Spatial Biology segment is anticipated to show solid growth, particularly in the spatial biology vertical, with revenues estimated at $92.5 million, a 5.7% increase from the previous year [6][9]. Group 3: Recent Developments and Innovations - Bio-Techne launched its Simple Western platform called Leo, which allows for high-throughput analysis of samples [4]. - The company expanded its geographic reach through new distribution agreements in Turkey and Azerbaijan, which may positively impact revenue [4]. - The Precision Diagnostic Tools business is experiencing growth, with a unique portfolio that continues to gain market share [7]. Group 4: Collaborations and Product Launches - Bio-Techne's Asuragen brand collaborated with Oxford Nanopore Technologies to launch a new genetic panel, which is expected to enhance business performance [9]. - The company also expanded its menu of RNAscope in situ hybridization probes to support spatial biology research and next-generation therapeutics [8].

Core Insights - March Biosciences has been awarded a $200,000 G-Rex® Grant to advance the manufacturing of its lead asset, MB-105, a novel CAR-T cell therapy targeting CD5 for T-cell lymphomas [1][5]. Company Developments - The grant will support the development of a scalable cGMP process using the G-Rex bioreactor, aimed at reducing complexity, time, and costs in manufacturing autologous CAR-T products [2][4]. - March Biosciences is focused on overcoming scalability and efficiency barriers in the manufacturing of MB-105, with the support of Wilson Wolf Manufacturing [3][5]. - The G-Rex Grant will facilitate the establishment of a fully integrated CAR-T cell manufacturing process, enhancing the production capabilities for MB-105 and other CAR-T products in development [4][6]. Industry Context - The G-Rex Grant Program, which has awarded nearly 200 grants, aims to advance cell and gene-modified cell therapy (CGT) development and manufacturing, with individual grants worth up to $300,000 [6][8]. - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, indicating its significant role in the industry [8]. - March Biosciences' MB-105 has received U.S. FDA orphan drug designation for treating relapsed/refractory CD5-positive T-cell lymphoma, highlighting its potential in addressing unmet medical needs [5][14].

Core Insights - Bio-Techne Corporation has launched an Early Access Program for a new assay that enables high-resolution spatial visualization of protein interactions within complex tissues, enhancing the understanding of molecular signaling in disease processes [1][2] Group 1: New Assay Development - The new assay is based on Advanced Cell Diagnostics RNAscope™ technology and allows for in situ detection of protein proximity, providing a spatial solution for exploring functional interactions between proteins [1][2] - This technology addresses limitations of conventional methods that often lose spatial fidelity and do not provide localization data, thus offering a clear visual signal at subcellular resolution [2] Group 2: Research Applications - The assay is particularly valuable for research areas where context is crucial, such as immune checkpoint dynamics, bispecific antibodies, and protein interactions at synaptic junctions [2] - Proof-of-concept data and case studies will be presented at the 2025 American Association for Cancer Research (AACR) annual meeting, showcasing the assay's capabilities [3] Group 3: Company Overview - Bio-Techne Corporation is a global life sciences company that generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [4]

Core Insights - Bio-Techne Corporation will showcase its advancements in cancer research tools at the 2025 AACR Annual Meeting, highlighting its oncology research portfolio [1][2] Group 1: Company Overview - Bio-Techne is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [10] - The company has around 3,100 employees worldwide and offers a comprehensive portfolio of products to assist in scientific investigations and drug discovery [10] Group 2: Event Participation - At the AACR Annual Meeting, Bio-Techne will engage with researchers and industry professionals to present its cutting-edge solutions that support advancements in oncology [2] - The company will feature its oncology research portfolio at booth 3049, including high-performance proteins, antibodies, small molecules, and automated proteomic analysis platforms [3] Group 3: Specific Technologies and Presentations - Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will showcase its protease-free workflows for spatial multiomic research, enhancing capabilities for multiomic detection [3] - Lunaphore, another Bio-Techne brand, will present its fully-automated multiomics application for fixed-frozen tissue and host an exclusive dinner reception for the spatial biology community [4] Group 4: Research Presentations - Bio-Techne will conduct several poster presentations at the AACR, including topics such as protein quantitation for cancer therapeutics and multiomic co-detection in tumor microenvironments [6][7][8] - Specific presentations will cover evaluations of biomarkers in glioblastoma and immune cell phenotypes in various cancer types [6][8][9]

Core Insights - Cyber Enviro-Tech, Inc. (CETI) has successfully registered with Kuwait Oil Company (KOC), a significant milestone in its global growth strategy, allowing it to bid on a produced water remediation project valued at over $100 million annually [1][2] Group 1: Company Achievements - The registration process with KOC is rigorous, often taking over two years and costing more than a million dollars, making CETI's achievement particularly noteworthy [1] - CETI's CEO, Kim D. Southworth, highlighted the transformative opportunity this registration presents, enabling the company to showcase its Hybrid TDS SWD water remediation system, which can remove contaminants at levels up to 400 times greater than EPA standards [2] - The approval by KOC also provides CETI with broader access to the region through Kuwait Petroleum Corporation (KPC), facilitating potential business opportunities across the Middle East [2] Group 2: Technological Innovations - CETI's proprietary equipment and processes, tested in Oklahoma and Texas, feature convertible Zero Liquid Discharge (ZLD) capability, which could eliminate approximately 90 million gallons daily of fluid from current disposal methods [3] - The detoxification process developed by CETI can treat substantial volumes of contaminated water in under 30 minutes, allowing for safe secondary and tertiary uses while significantly reducing environmental concerns [3] Group 3: Strategic Partnerships - The achievement follows over a year of collaboration with Delta World Environmental Solutions, CETI's exclusive partner in the Middle East, which has been instrumental in building necessary relationships for deploying CETI's systems [4] - Southworth credited DELTA's CEO, Serdar Guerel, for his pivotal role in advancing environmentally responsible projects across Turkey and the Middle East [5] Group 4: Company Overview - Cyber Enviro-Tech, Inc. operates internationally in eco-conscious remediation projects, utilizing proprietary bio remedial materials and advanced technologies to eliminate hazardous waste from various sources [6] - The company integrates Fourth Industrial Revolution technologies, including machine learning and artificial intelligence, alongside non-chemical bioremediation techniques [6]

Core Insights - Bio-Techne (TECH) shares increased by 10.8% to $54.07, following a significant trading volume, contrasting with a 16.5% decline over the past four weeks [1] - The stock's rise is attributed to investor optimism ahead of its fiscal 2025 Q3 financial results, set to be released on May 7 [2] - The company is projected to report quarterly earnings of $0.52 per share, reflecting an 8.3% year-over-year increase, with expected revenues of $316.3 million, a 4.2% increase from the previous year [3] Earnings Estimates and Trends - The consensus EPS estimate for Bio-Techne has remained stable over the last 30 days, indicating that stock price movements may not sustain without changes in earnings estimate revisions [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Context - Bio-Techne operates within the Zacks Medical - Biomedical and Genetics industry, where NovoCure (NVCR) also resides, having experienced a 10.3% increase to $16.95, despite a -27.9% return over the past month [4] - NovoCure's consensus EPS estimate has remained unchanged at -$0.47, representing a -30.6% change compared to the previous year, and it currently holds a Zacks Rank of 4 (Sell) [5]